title: [Two phases of the contingent negative variation in humans: connection with motor and mental functions].
abstract: The question of dependence of the contingent negative variation (CNV) on the regulating mechanisms of motor and mental functions is not sufficiently studied. The tasks of the present work were: to investigate the dependence of the CNV early and late phases on the state of motor and mental functions in patients with Parkinson's disease (PD), and to elucidate the levodopa influence on the CNV parameters. 18 healthy subjects and 56 patients with PD were studied. In PD patients, significant reductions of amplitudes and squares of two CNV phases were observed. A negative correlation of the degree of coordinating muscle relationships disturbance with amplitudes of two CNV phases was found (p < 0.01). A positive interdependence between values of the both CNV phases and the state of mental functions was established, memory in particular (p < 0.05). After levodopa administration in PD patients, the early CNV phase did not significantly change, whereas the late CNV phase significantly increased (p < 0.05). Results of the investigation suggest an important role of the structures ensuring both direct motor control and mental functions in two CNV phases formation. A more obvious levodopa influence on the late CNV phase suggest participation of the basal ganglia efferent system in generation of the late CNV phase rather than in organization of the early CNV phase.
authors.forename: E P
authors.initials: EP
authors.lastname: Lukhanina
authors.forename: I N
authors.initials: IN
authors.lastname: Karaban'
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Burenok
authors.forename: N A
authors.initials: NA
authors.lastname: Mel'nik
authors.forename: N M
authors.initials: NM
authors.lastname: Berezetskaia
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000494:pharmacology; D003265:Contingent Negative Variation / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000502:physiology*; D010300:Parkinson Disease / Q000503:physiopathology*; D013850:Thinking / Q000502:physiology*
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa